☆ 4.7 Review

Pruritogenic Mediators and New Antipruritic Drugs in Atopic Dermatitis

JOURNAL OF CLINICAL MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Review Dermatology

Efficacy and safety of topical JAK inhibitors in the treatment of atopic dermatitis in paediatrics and adults: A systematic review

Sara Sadeghi et al.

Summary: Atopic dermatitis (AD) is a common inflammatory skin disease with dysregulated immune systems. JAKi show promise as a novel treatment for AD by reducing pro-inflammatory cytokine production. A systematic review was conducted to evaluate the efficacy and safety of topical JAKi in adults and pediatrics with AD. The review identified 19 studies demonstrating the effectiveness of topical delgocitinib, tofacitinib, ruxolitinib, cerdulatinib, and ifidancitinib in improving AD symptoms. Minimal adverse effects were observed with topical JAKi. Further studies are needed for longer-term assessment and comparative trials.

EXPERIMENTAL DERMATOLOGY (2023)

Add to Collection

Letter Dermatology

Tralokinumab in the treatment of resistant atopic dermatitis: An open-label, retrospective case series study

Elena Pezzolo et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Add to Collection

Review Dermatology

Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis

Sheridan M. Hoy

Summary: Ruxolitinib cream 1.5% is an alternative topical agent for the treatment of mild to moderate atopic dermatitis (AD) in adults and adolescents. It showed improvements in measures of disease severity, pruritus, and sleep disturbance when applied twice daily for 8 weeks, and disease severity was controlled for the next 44 weeks. Ruxolitinib cream 1.5% was well tolerated and had a similar safety profile to the vehicle cream.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2023)

Add to Collection

Letter Dermatology

Effectiveness of dupilumab for chronic prurigo in elderly patients with atopic dermatitis

Shinji Mitsuyama et al.

ANAIS BRASILEIROS DE DERMATOLOGIA (2023)

Add to Collection

Article Dermatology

Validation of diagnostic criteria for atopic dermatitis and proposal of novel diagnostic criteria for adult and elderly Chinese populations: a multicentre, prospective, clinical setting-based study

Wanbo Yue et al.

Summary: This study aimed to validate the diagnostic efficacy of three sets of AD criteria in adult and elderly Chinese populations in a hospital setting. The Chinese criteria of atopic dermatitis for children (CCAD) showed high sensitivity and favorable diagnostic efficacy, making it suitable for the diagnosis of atopic dermatitis in adult and elderly Chinese populations, particularly for mild and moderate cases of the condition.

BRITISH JOURNAL OF DERMATOLOGY (2023)

Add to Collection

Review Ophthalmology

Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin-Induced Adverse Ocular Events-Incidence, Etiology, and Management

Tomas Mickevicius et al.

Summary: Emerging monoclonal antibody therapies are increasingly important for severe and refractory immune-driven and oncological disorders, but they can induce adverse ocular events (AOEs) that require discontinuation or additional management. This study provides current knowledge on AOEs associated with three monoclonal antibody therapies (dupilumab, tralokinumab, and belantamab mafodotin), including manifestations, pathophysiological mechanisms, and treatment recommendations. Conjunctivitis was the most common AOE in patients receiving dupilumab or tralokinumab for atopic dermatitis. Mild cases were managed with warm compresses, artificial tears, and antihistamine/mast cell stabilizer eye drops. Severe cases required additional anti-inflammatory therapy with corticosteroid eye drops or topical calcineurin inhibitors. Patients with refractory multiple myeloma treated with belantamab mafodotin often developed keratopathy, which may require contact lens fitting or delayed treatment cycles.

CORNEA (2023)

Add to Collection

Article Dermatology

Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7)

J. Gutermuth et al.

Summary: The study evaluated the efficacy and safety of tralokinumab plus TCS in adult patients with severe AD not adequately controlled with CSA or with contraindications to oral CSA, showing the treatment was effective and well tolerated.

BRITISH JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Article Dermatology

Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies

K. Kabashima et al.

Summary: Long-term administration of nemolizumab in patients with inadequately controlled moderate-to-severe pruritus in AD showed continuous improvement in pruritus, signs of AD, and quality of life for up to 68 weeks, with a favorable safety profile, based on two long-term phase III studies.

BRITISH JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Review Dermatology

Effects of systemic therapies on pruritus in adults with atopic dermatitis: a systematic review and meta-analysis

X. L. Tan et al.

Summary: Pruritus is a common symptom of atopic dermatitis and affects patients' quality of life. This study compared the effectiveness of various systemic therapies in relieving pruritus in adults with moderate to severe AD. Results showed that most systemic therapies were superior to placebo in reducing pruritus, with dupilumab and nemolizumab showing particularly promising results. Further head-to-head trials are needed for conclusive evidence.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2022)

Add to Collection

Article Allergy

Mechanistic insights into the antipruritic effects of lebrikizumab, an anti-IL-13 mAb

Yannick Miron et al.

Summary: These preclinical findings indicate that IL-13 plays a direct enhancer role in multiple itch and neuroactive pathways as well as transcriptional downstream effects, providing insights into the mechanistic basis for lebrikizumab's anti-itch effects.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

Add to Collection

Review Neurosciences

The translational revolution of itch

Brian S. Kirri

Summary: This article introduces the importance of itch sensation for survival and its value in the field of medicine, highlighting how research in itch biology has led to important discoveries and breakthroughs in treatment.

NEURON (2022)

Add to Collection

Review Immunology

Safety and Efficacy of Nemolizumab for Atopic Dermatitis With Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials

Junqin Liang et al.

Summary: This study evaluated the efficacy of nemolizumab in treating patients with atopic dermatitis and found that it significantly reduced pruritus symptoms and severity, improving patients' quality of life.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Review Cell Biology

An Altered Skin and Gut Microbiota Are Involved in the Modulation of Itch in Atopic Dermatitis

Catharina Sagita Moniaga et al.

Summary: Skin and gut microbiota play important roles in the pathogenesis of atopic dermatitis (AD). The diversity of microbiota is altered in AD, and this alteration is correlated with disease severity, especially in the lesional skin. Recent evidence suggests that microbiota might affect itch in AD through gut-skin-brain interactions. Microbial metabolites, proinflammatory cytokines, and impaired immune response contribute to histamine-independent itch, disruption of the epidermal barrier, and central sensitization of itch mechanisms. Probiotics have shown positive effects in alleviating itch in AD, indicating potential novel strategies for managing itchy skin in AD patients.

CELLS (2022)

Add to Collection

Review Medicine, General & Internal

Efficacy of topical and systemic treatments for atopic dermatitis on pruritus: A systematic literature review and meta-analysis

Youna Rodriguez-Le Roy et al.

Summary: This study reviewed the literature on the effects of AD treatments on pruritus and conducted a meta-analysis. The results showed that most treatments had a positive effect on pruritus, but the degree of improvement varied among different treatments.

FRONTIERS IN MEDICINE (2022)

Add to Collection

Review Medicine, General & Internal

Potential biomarkers of atopic dermatitis

Ling Yu et al.

Summary: Atopic dermatitis is a chronic inflammatory skin disease with a wide range of variations. Biomarkers play a crucial role in guiding personalized treatment. The development of technology has provided new insights into potential biomarkers, and non-invasive methods have been used to explore different profiles of patients' skin. Several potential biomarkers have been identified for AD diagnosis, disease severity monitoring, comorbidity prediction, and treatment effects evaluation.

FRONTIERS IN MEDICINE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Serum Levels of Eosinophil-Derived Neurotoxin, Platelet-Activating Factor and Vascular Endothelial Growth Factor in Adult Patients with Atopic Dermatitis-A Pilot Study

Krzysztof Gomulka et al.

Summary: Atopic dermatitis is a chronic, highly pruritic, relapsing-remitting inflammatory skin disease. This study found that the serum levels of EDN and VEGF were significantly increased in patients with AD, while the level of PAF showed no significant difference. In AD patients, there was a positive correlation between the EDN level and the severity of the disease.

BIOMEDICINES (2022)

Add to Collection

Review Immunology

The efficacy and safety of IL-13 inhibitors in atopic dermatitis: A systematic review and meta-analysis

Yan Zhang et al.

Summary: IL-13 inhibitors lebrikizumab and tralokinumab have demonstrated good efficacy and safety in the treatment of moderate to severe AD. Compared to placebo treatment, these IL-13 inhibitors can significantly improve skin symptoms and quality of life in patients with AD, albeit with a higher risk of conjunctivitis.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Review Dermatology

Managing Atopic Dermatitis with Lebrikizumab - The Evidence to Date

Angelina Labib et al.

Summary: Atopic dermatitis is a common inflammatory skin disease, and lebrikizumab, an interleukin 13 monoclonal antibody inhibitor, shows promising results in its treatment. Studies have demonstrated that lebrikizumab is effective in improving symptoms of eczema and has an acceptable safety profile.

CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2022)

Add to Collection

Article Neurosciences

Inhibitory effects of antibiotic-induced gut microbiota depletion on acute itch behavior in mice

Qinqin Zhang et al.

Summary: This study discovered that antibiotic-induced depletion of gut microbiota could reduce acute itch behavior, possibly connected with decreased neuronal activity in the trigeminal ganglia.

BRAIN RESEARCH BULLETIN (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Serum Levels of Vascular Endothelial Growth Factor, Platelet Activating Factor and Eosinophil-Derived Neurotoxin in Chronic Spontaneous Urticaria-A Pilot Study in Adult Patients

Krzysztof Gomulka et al.

Summary: This study aimed to investigate the serum levels of VEGF, PAF, and EDN in relation to disease activity and pruritus intensity in adult patients with CSU. The results showed higher levels of VEGF, PAF, and EDN in CSU patients compared with healthy subjects, but these cytokines were not significantly correlated with disease activity or pruritus intensity.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Allergy

Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis

Marcus Maurer et al.

Summary: In patients with atopic dermatitis, astegolimab did not show a significant difference compared to placebo for the primary or secondary outcomes.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Elevated Level of Serum Neurotrophin-4, but Not of Brain-Derived Neurotrophic Factor, in Patients with Chronic Kidney Disease-Associated Pruritus

Kamila Wala-Zielinska et al.

Summary: Chronic kidney disease-associated pruritus (CKD-aP) is a bothersome condition that severely affects the quality of life of patients with advanced chronic kidney disease (CKD). This study assessed the serum levels of neurotrophin-4 (NT-4) and brain-derived neurotrophic factor (BDNF) in hemodialysis patients with and without CKD-aP. The results showed a significantly higher level of NT-4 in the group with pruritus, indicating its potential role in the pathophysiology of pruritus in dialysis patients. No significant difference or correlation was found for BDNF levels.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Review Immunology

Interrelationship and Sequencing of Interleukins 4, 13, 31, and 33-An Integrated Systematic Review: Dermatological and Multidisciplinary Perspectives

Alin Laurentiu Tatu et al.

Summary: This article summarizes the roles of IL-4, IL-13, IL-31, and IL-33 from a multi-disciplinary perspective, highlighting the importance and potential value of interleukins in various organ system pathologies.

JOURNAL OF INFLAMMATION RESEARCH (2022)

Add to Collection

Article Allergy

Inhibition of mite-induced dermatitis, pruritus, and nerve sprouting in mice by the endothelin receptor antagonist bosentan

Makiko Kido-Nakahara et al.

Summary: The study showed that inhibiting Endothelin-1 could effectively alleviate skin inflammation and itch in a murine AD model, reducing scratching bouts, serum levels, and specific gene expressions. Therefore, Endothelin-1 may be a potential therapeutic target for treating atopic inflammation and itch.

ALLERGY (2021)

Add to Collection

Article Dermatology

Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial

J. I. Silverberg et al.

Summary: The study demonstrates that tralokinumab in combination with TCS is effective and well tolerated in patients with moderate-to-severe AD; high dose tralokinumab showed superior efficacy compared to placebo at 16 weeks. Patients who continued tralokinumab treatment at week 32 maintained response. The overall incidence of adverse events was similar across treatment groups.

BRITISH JOURNAL OF DERMATOLOGY (2021)

Add to Collection

Article Dermatology

Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)

A. Wollenberg et al.

Summary: Tralokinumab monotherapy was found to be superior to placebo at 16 weeks of treatment in two 52-week phase III trials, ECZTRA 1 and ECZTRA 2, and was well tolerated up to 52 weeks of treatment with sustained efficacy.

BRITISH JOURNAL OF DERMATOLOGY (2021)

Add to Collection

Article Allergy

Dual function of Langerhans cells in skin TSLP-promoted TFH differentiation in mouse atopic dermatitis

Pierre Marschall et al.

Summary: This study explores the dual functionality of Langerhans cells (LCs) in TSLP-promoted TFH and T(H)2 differentiation in atopic dermatitis (AD) pathogenesis, demonstrating that LCs play different roles in different mouse models of AD, promoting TFH/GC response in one model and inhibiting it in another.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Dermatology

Disease severity and trigger factors in Danish children with atopic dermatitis: a nationwide study

T. Gerner et al.

Summary: This study identified factors associated with severe AD in childhood, including early onset, multiple body regions affected, history of hay fever, female gender, and low maternal education level. The study also showed that severe AD can result in children staying home from school, concentration problems, and sleep disturbances, with cold weather, chlorinated water, and warm weather being the most commonly reported triggers of AD.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

A basophil-neuronal axis promotes itch

Fang Wang et al.

Summary: The study identifies that a large proportion of patients with atopic dermatitis (AD) harbor allergen-specific immunoglobulin E (IgE) and exhibit a propensity for acute itch flares. It also shows that in AD-associated inflammation, a previously unrecognized basophil-leukotriene (LT) axis emerges as critical for acute itch flares.

CELL (2021)

Add to Collection

Review Medicine, Research & Experimental

Multifactorial expression of IL-6 with update on COVID-19 and the therapeutic strategies of its blockade (Review)

Elena Niculet et al.

Summary: IL-6 is a cytokine with both pro-inflammatory and anti-inflammatory properties, and plays a key role in regulating various physiological and pathological processes. Its signaling is involved in coronary artery disease and the global COVID-19 pandemic, and is closely associated with certain cardiovascular risk factors.

EXPERIMENTAL AND THERAPEUTIC MEDICINE (2021)

Add to Collection

Article Dermatology

Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study

Hidemi Nakagawa et al.

Summary: The study evaluated the efficacy and safety of Delgocitinib ointment in Japanese pediatric patients with AD. Results showed significant improvement in AD in the short term and maintenance of improvement with long-term use.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Article Dermatology

Baricitinib in patients with moderate-tosevere atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)

Eric L. Simpson et al.

Summary: The study evaluated the efficacy and safety of baricitinib monotherapy in patients with moderate-to-severe AD who responded inadequately or were intolerant to topical therapy. Results showed a higher proportion of patients achieving efficacy endpoints in the baricitinib groups at week 16.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Genetic priming of sensory neurons in mice that overexpress PAR2 enhances allergen responsiveness

Joao M. Braz et al.

Summary: The study found that untreated Grhl3(PAR2/+) mice had up-regulation of trigeminal ganglia genes, and HDM treatment exacerbated this up-regulation, particularly in TG neurons expressing TRPV1. These transcriptional changes sensitize animals to allergens and contribute to pruritus in atopic skin disease.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Add to Collection

Article Dermatology

Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies

Kim Papp et al.

Summary: The study evaluated the efficacy and safety of RUX cream in patients with AD, showing significant effects on reducing itch and improving skin inflammation, with superior efficacy compared to vehicle cream and good tolerability.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

Thomas Bieber et al.

Summary: The study demonstrated that both 200 mg and 100 mg doses of abrocitinib showed significant efficacy in treating moderate-to-severe atopic dermatitis compared to placebo, with the 200 mg dose being superior to dupilumab in improving itch response. Neither dose of abrocitinib showed significant differences from dupilumab in most other key secondary endpoints at week 16.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Itch in Atopic Dermatitis - What Is New?

Franz J. Legat

Summary: Atopic dermatitis is a common inflammatory skin disease affecting up to 20% of children and 10% of adults in higher income countries, with chronic pruritus as a major symptom causing significant impact on quality of life. New systemic and topical treatments targeting specific cytokines and receptors have ushered in a new era in atopic dermatitis and pruritus therapy.

FRONTIERS IN MEDICINE (2021)

Add to Collection

Review Biochemistry & Molecular Biology

The Implications of Pruritogens in the Pathogenesis of Atopic Dermatitis

Lai-San Wong et al.

Summary: Atopic dermatitis is a prototypic inflammatory disease characterized by intense itching, with multifactorial pathophysiology involving environmental factors, genetic susceptibility, skin barrier function, and immune responses. Recent research has shown that pruritogens not only trigger itch but also interact with immune cells and act as inflammatory mediators, worsening the severity of atopic dermatitis. Targeted therapies for atopic dermatitis focus on the interaction between pruritogens and inflammatory molecules.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

Kristian Reich et al.

Summary: This study evaluated the efficacy and safety of upadacitinib in combination with topical corticosteroids for moderate-to-severe atopic dermatitis, showing that upadacitinib was more effective and well tolerated compared to placebo.

LANCET (2021)

Add to Collection

Article Dermatology

Relationship of Substance P with the Degree of Atopic Dermatitis Severity

Deryne Anggia Paramita et al.

Summary: Atopic dermatitis is a chronic inflammatory skin disease that commonly starts in childhood. Substance P is believed to play a crucial role in inducing itching in AD. This study aimed to analyze the relationship between serum substance P levels and AD severity in children, but found no significant correlation between substance P levels and AD severity or SCORAD values. Further research with a larger sample size and diverse population may be needed to generalize the findings.

CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2021)

Add to Collection

Article Allergy

Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus

Jonathan Silverberg et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)

Add to Collection

Letter Dermatology

IL-17A Induces Endothelin-1 Expression through p38 Pathway in Prurigo Nodularis

Lai-San Wong et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2020)

Add to Collection

Review Dermatology

Neuroimmune interactions in chronic itch of atopic dermatitis

G. Yosipovitch et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)

Add to Collection

Article Allergy

Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial

Emma Guttman-Yassky et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Multifaceted Analyses of Epidermal Serine Protease Activity in Patients with Atopic Dermatitis

Hayato Nomura et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection

Article Dermatology

Kallikrein 7 Promotes Atopic Dermatitis-Associated Itch Independently of Skin Inflammation

Changxiong J. Guo et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2020)

Add to Collection

Article Dermatology

Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study

Hidemi Nakagawa et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

Add to Collection

Review Physiology

PHYSIOLOGY AND PATHOPHYSIOLOGY OF ITCH

Ferda Cevikbas et al.

PHYSIOLOGICAL REVIEWS (2020)

Add to Collection

Article Dermatology

Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis A Phase 2b Randomized Clinical Trial

Emma Guttman-Yassky et al.

JAMA DERMATOLOGY (2020)

Add to Collection

Article Rheumatology

Translating IL-6 biology into effective treatments

Ernest H. Choy et al.

NATURE REVIEWS RHEUMATOLOGY (2020)

Add to Collection

Article Dermatology

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis A Randomized Clinical Trial

Jonathan Silverberg et al.

JAMA DERMATOLOGY (2020)

Add to Collection

Article Immunology

Protease-Activated Receptor-2 Regulates Neuro-Epidermal Communication in Atopic Dermatitis

Timo Buhl et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Eric L Simpson et al.

LANCET (2020)

Add to Collection

Article Medicine, General & Internal

Atopic dermatitis

Sinéad M Langan et al.

LANCET (2020)

Add to Collection

Article Medicine, General & Internal

Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus

Kenji Kabashima et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Dermatology

Clinical Relevance of Skin Pain in Atopic Dermatitis

Sonja Stander et al.

JOURNAL OF DRUGS IN DERMATOLOGY (2020)

Add to Collection

Review Dermatology

Possible roles of basophils in chronic itch

Takashi Hashimoto et al.

EXPERIMENTAL DERMATOLOGY (2019)

Add to Collection

Article Allergy

Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb

Andreas Wollenberg et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)

Add to Collection

Article Dermatology

Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study

Emma Guttman-Yassky et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)

Add to Collection

Article Immunology

Tachykinin upregulation in atopic dermatitis

Louise Lonndahl et al.

IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2019)

Add to Collection

Review Medicine, Research & Experimental

Neuro-immune crosstalk and allergic inflammation

Hiroki Kabata et al.

JOURNAL OF CLINICAL INVESTIGATION (2019)

Add to Collection

Article Dermatology

PAR2 Pepducin-Based Suppression of Inflammation and Itch in Atopic Dermatitis Models

Travis P. Barr et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)

Add to Collection

Letter Immunology

Stratum corneum interleukin-33 expressions correlate with the degree of lichenification and pruritus in atopic dermatitis lesions

Naomi Nakamura et al.

CLINICAL IMMUNOLOGY (2019)

Add to Collection

Letter Dermatology

Stratum corneum Toll-like receptor 3 expressions correlate with the severity of atopic dermatitis lesions

Naomi Nakamura et al.

JOURNAL OF DERMATOLOGICAL SCIENCE (2019)

Add to Collection

Letter Dermatology

TLR3 in Chronic Human Itch: A Keratinocyte-Associated Mechanism of Peripheral Itch Sensitization

Attila Gabor Szollosi et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)

Add to Collection

Article Dermatology

Role of SNAREs in Atopic Dermatitis-Related Cytokine Secretion and Skin-Nerve Communication

Jianghui Meng et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)

Add to Collection

Article Biochemistry & Molecular Biology

IL-6/p-BTK/p-ERK signaling mediates calcium phosphate-induced pruritus

Sunita Keshari et al.

FASEB JOURNAL (2019)

Add to Collection

Article Dermatology

Long-term safety and efficacy of rupatadine in Japanese patients with itching due to chronic spontaneous urticaria, dermatitis, or pruritus: A 12-month, multicenter, open-label clinical trial

Michihiro Hide et al.

JOURNAL OF DERMATOLOGICAL SCIENCE (2019)

Add to Collection

Article Biochemistry & Molecular Biology

IL-4 Augments IL-31/IL-31 Receptor Alpha Interaction Leading to Enhanced Ccl 17 and Ccl 22 Production in Dendritic Cells: Implications for Atopic Dermatitis

Sho Miake et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

Add to Collection

Letter Dermatology

Interleukin-4 and interleukin-13 evoke scratching behaviour in mice

Michelle Campion et al.

EXPERIMENTAL DERMATOLOGY (2019)

Add to Collection

Review Dermatology

Interleukin-33 in atopic dermatitis

Yasutomo Imai

JOURNAL OF DERMATOLOGICAL SCIENCE (2019)

Add to Collection

Article Cell Biology

Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis

Yi-Ling Chen et al.

SCIENCE TRANSLATIONAL MEDICINE (2019)

Add to Collection

Article Physiology

Requirement for neuropeptide Y in the development of type 2 responses and allergen-induced airway hyperresponsiveness and inflammation

Naohiro Oda et al.

AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2019)

Add to Collection

Article Biology

Neutrophils promote CXCR3-dependent itch in the development of atopic dermatitis

Carolyn M. Walsh et al.

ELIFE (2019)

Add to Collection

Article Dermatology

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis A Phase 2 Randomized Clinical Trial

Melinda J. Gooderham et al.

JAMA DERMATOLOGY (2019)

Add to Collection

Review Immunology

The Role of Toll-Like Receptors in Skin Host Defense, Psoriasis, and Atopic Dermatitis

Lixiang Sun et al.

JOURNAL OF IMMUNOLOGY RESEARCH (2019)

Add to Collection

Article Immunology

Analysis of the Association of Polymorphisms rs5743708 in TLR2 and rs4986790 in TLR4 with Atopic Dermatitis Risk

Yuan Zhang et al.

IMMUNOLOGICAL INVESTIGATIONS (2019)

Add to Collection

Review Allergy

Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis

Thomas Werfel et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)

Add to Collection

Article Dermatology

Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial

Eric L. Simpson et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)

Add to Collection

Article Dermatology

Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis

Wenhui Wei et al.

JOURNAL OF DERMATOLOGY (2018)

Add to Collection

Article Dermatology

Substance P Antagonist Aprepitant Shows no Additive Effect Compared with Standardized Topical Treatment Alone in Patients with Atopic Dermatitis

Louise Lonndahl et al.

ACTA DERMATO-VENEREOLOGICA (2018)

Add to Collection

Article Allergy

New mechanism underlying IL-31-induced atopic dermatitis

Jianghui Meng et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)

Add to Collection

Article Immunology

Platelet-Activating Factor-Induced Reduction in Contact Hypersensitivity Responses Is Mediated by Mast Cells via Cyclooxygenase-2-Dependent Mechanisms

Jesus A. Ocana et al.

JOURNAL OF IMMUNOLOGY (2018)

Add to Collection

Review Dermatology

Dupilumab: A review of its use in the treatment of atopic dermatitis

Melinda J. Gooderham et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)

Add to Collection

Article Dermatology

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)

Eric L. Simpson et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)

Add to Collection

Review Clinical Neurology

Clinical presentation, management, and pathophysiology of neuropathic itch

Martin Steinhoff et al.

LANCET NEUROLOGY (2018)

Add to Collection

Review Immunology

Thymic Stromal Lymphopoietin Isoforms, Inflammatory Disorders, and Cancer

Gilda Varricchi et al.

FRONTIERS IN IMMUNOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Atopic dermatitis

Stephan Weidinger et al.

NATURE REVIEWS DISEASE PRIMERS (2018)

Add to Collection

Article Oncology

Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?

Ali Berkant Avci et al.

BIODRUGS (2018)

Add to Collection

Article Allergy

The pruritogenic mediator endothelin-1 shifts the dendritic cell-T-cell response toward Th17/Th1 polarization

T. Nakahara et al.

ALLERGY (2018)

Add to Collection

Article Immunology

Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells

Sylvia Heink et al.

NATURE IMMUNOLOGY (2017)

Add to Collection

Article Allergy

Persistent kallikrein 5 activation induces atopic dermatitis-like skin architecture independent of PAR2 activity

Yanan Zhu et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)

Add to Collection

Review Allergy

Therapeutic pipeline for atopic dermatitis: End of the drought?

Amy S. Paller et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)

Add to Collection

Article Dermatology

The role of toll-like receptor 3 in chronic contact hypersensitivity induced by repeated elicitation

Risa Yasuike et al.

JOURNAL OF DERMATOLOGICAL SCIENCE (2017)

Add to Collection

Review Dermatology

Interleukin-31 pathway and its role in atopic dermatitis: a systematic review

Mohammed D. Saleem et al.

JOURNAL OF DERMATOLOGICAL TREATMENT (2017)

Add to Collection

Article Immunology

TSLP-activated dendritic cells induce human T follicular helper cell differentiation through OX40-ligand

Lucia Pattarini et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2017)

Add to Collection

Review Immunology

Role of Substance P Neuropeptide in Inflammation, Wound Healing, and Tissue Homeostasis

Susmit Suvas

JOURNAL OF IMMUNOLOGY (2017)

Add to Collection

Article Immunology

Expression of IL-22 in the Skin Causes Th2-Biased Immunity, Epidermal Barrier Dysfunction, and Pruritus via Stimulating Epithelial Th2 Cytokines and the GRP Pathway

Hongfei Lou et al.

JOURNAL OF IMMUNOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Andrew Blauvelt et al.

LANCET (2017)

Add to Collection

Article Biochemistry & Molecular Biology

Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch

Landon K. Oetjen et al.

CELL (2017)

Add to Collection

Review Immunology

Mechanisms and consequences of Jak-STAT signaling in the immune system

Alejandro V. Villarino et al.

NATURE IMMUNOLOGY (2017)

Add to Collection

Article Dermatology

Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial

R. Bissonnette et al.

BRITISH JOURNAL OF DERMATOLOGY (2016)

Add to Collection

Review Biochemistry & Molecular Biology

Neuropeptide substance P and the immune response

Alireza Mashaghi et al.

CELLULAR AND MOLECULAR LIFE SCIENCES (2016)

Add to Collection

Review Allergy

Lipid Mediators of Allergic Disease: Pathways, Treatments, and Emerging Therapeutic Targets

Eric Schauberger et al.

CURRENT ALLERGY AND ASTHMA REPORTS (2016)

Add to Collection

Review Geriatrics & Gerontology

Atopic dermatitis in older adults: A viewpoint from geriatric dermatology

Ryoji Tanei et al.

GERIATRICS & GERONTOLOGY INTERNATIONAL (2016)

Add to Collection

Article Allergy

The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves

Micha Feld et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)

Add to Collection

Article Medicine, General & Internal

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

E. L. Simpson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Multidisciplinary Sciences

IL-33/ST2 signaling excites sensory neurons and mediates itch response in a mouse model of poison ivy contact allergy

Boyi Liu et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)

Add to Collection

Article Multidisciplinary Sciences

Distinct roles of short and long thymic stromal lymphopoietin isoforms in house dust mite-induced asthmatic airway epithelial barrier disruption

Hangming Dong et al.

SCIENTIFIC REPORTS (2016)

Add to Collection

Review Chemistry, Medicinal

Multiple Functions of the New Cytokine-Based Antimicrobial Peptide Thymic Stromal Lymphopoietin (TSLP)

Louise Bjerkan et al.

PHARMACEUTICALS (2016)

Add to Collection

Article Dermatology

Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis

David Roblin et al.

ACTA DERMATO-VENEREOLOGICA (2015)

Add to Collection

Review Physiology

Calcitonin gene-related peptide: key regulator of cutaneous immunity

R. D. Granstein et al.

ACTA PHYSIOLOGICA (2015)

Add to Collection

Article Allergy

Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities

C. G. Mortz et al.

ALLERGY (2015)

Add to Collection

Article Allergy

Mutual upregulation of endothelin-1 and IL-25 in atopic dermatitis

M. K. Aktar et al.

ALLERGY (2015)

Add to Collection

Article Allergy

Plasma endothelin-1 levels during exacerbation of atopic dermatitis

Namjil N. Tsybikov et al.

ALLERGY AND ASTHMA PROCEEDINGS (2015)

Add to Collection

Letter Dermatology

Serum gastrin-releasing peptide levels correlate with disease severity and pruritus in patients with atopic dermatitis

A. Tirado-Sanchez et al.

BRITISH JOURNAL OF DERMATOLOGY (2015)

Add to Collection

Letter Allergy

Thymic stromal lymphopoietin downregulates filaggrin expression by signal transducer and activator of transcription 3 (STAT3) and extracellular signal-regulated kinase (ERK) phosphorylation in keratinocytes

Jin Hee Kim et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)

Add to Collection

Article Biochemistry & Molecular Biology

Prerequisites for Functional Interleukin 31 Signaling and Its Feedback Regulation by Suppressor of Cytokine Signaling 3 (SOCS3)

Elisabeth Maier et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2015)

Add to Collection

Article Dermatology

TSLP Directly Interacts with Skin-Homing Th2 Cells Highly Expressing its Receptor to Enhance IL-4 Production in Atopic Dermatitis

Kazuki Tatsuno et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)

Add to Collection

Article Genetics & Heredity

Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis

Lavinia Paternoster et al.

NATURE GENETICS (2015)

Add to Collection

Article Biochemistry & Molecular Biology

STAT3-dependent reactive astrogliosis in the spinal dorsal horn underlies chronic itch

Miho Shiratori-Hayashi et al.

NATURE MEDICINE (2015)

Add to Collection

Article Neurosciences

HTR7 Mediates Serotonergic Acute and Chronic Itch

Takeshi Morita et al.

NEURON (2015)

Add to Collection

Review Physiology

The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases

D. Ganea et al.

ACTA PHYSIOLOGICA (2015)

Add to Collection

Article Dermatology

Epidemiology of atopic dermatitis in Poland according to the Epidemiology of Allergic Disorders in Poland (ECAP) study

Adam J. Sybilski et al.

JOURNAL OF DERMATOLOGY (2015)

Add to Collection

Article Psychiatry

Serotonin and interleukin-6: Association with pruritus severity, sleep quality and depression severity in Prurigo Nodularis

Deepthi Konda et al.

ASIAN JOURNAL OF PSYCHIATRY (2015)

Add to Collection

Article Dermatology

Epidemiology of Chronic Pruritus: Where Have We Been and Where Are We Going?

Nicholas K. Mollanazar et al.

CURRENT DERMATOLOGY REPORTS (2015)

Add to Collection

Editorial Material Dermatology

Is Adult Atopic Eczema More Common Than We Think? - A Population-based Study in Danish Adults

Gabrielle R. Vinding et al.

ACTA DERMATO-VENEREOLOGICA (2014)

Add to Collection

Article Allergy

Mechanisms of abnormal lamellar body secretion and the dysfunctional skin barrier in patients with atopic dermatitis

Peter M. Elias et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)

Add to Collection

Article Allergy

A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1

Ferda Cevikbas et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)

Add to Collection

Article Medicine, Research & Experimental

Neural peptidase endothelin-converting enzyme 1-regulates endothelin induced pruritus

Makiko Kido-Nakahara et al.

JOURNAL OF CLINICAL INVESTIGATION (2014)

Add to Collection

Article Dermatology

Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: Inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP

Tsugunobu Andoh et al.

JOURNAL OF DERMATOLOGICAL SCIENCE (2014)

Add to Collection

Article Dermatology

Increased serum levels of interleukin 33 in patients with atopic dermatitis

Risa Tamagawa-Mineoka et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)

Add to Collection

Article Medicine, General & Internal

Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses

Gail M. Gauvreau et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Allergy

IL-33 Promotes the Induction and Maintenance of Th2 Immune Responses by Enhancing the Function of OX40 Ligand

Naoko Murakami-Satsutani et al.

ALLERGOLOGY INTERNATIONAL (2014)

Add to Collection

Article Pathology

Protease Activity Enhances Production of Thymic Stromal Lymphopoietin and Basophil Accumulation in Flaky Tail Mice

Catharina S. Moniaga et al.

AMERICAN JOURNAL OF PATHOLOGY (2013)

Add to Collection

Article Biochemistry & Molecular Biology

The Epithelial Cell-Derived Atopic Dermatitis Cytokine TSLP Activates Neurons to Induce Itch

Sarah R. Wilson et al.

CELL (2013)

Add to Collection

Article Dermatology

TSLP Produced by Keratinocytes Promotes Allergen Sensitization through Skin and Thereby Triggers Atopic March in Mice

Juan Manuel Leyva-Castillo et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)

Add to Collection

Article Allergy

Neurogenic markers of the inflammatory process in atopic dermatitis: relation to the severity and pruritus

Ewa Teresiak-Mikolajczak et al.

POSTEPY DERMATOLOGII I ALERGOLOGII (2013)

Add to Collection

Article Endocrinology & Metabolism

Keratinocytes express cytokines and nerve growth factor in response to neuropeptide activation of the ERK1/2 and JNK MAPK transcription pathways

Xiaoyou Shi et al.

REGULATORY PEPTIDES (2013)

Add to Collection

Article Dermatology

Eczema among adults: prevalence, risk factors and relation to airway diseases. Results from a large-scale population survey in Sweden

E. P. Ronmark et al.

BRITISH JOURNAL OF DERMATOLOGY (2012)

Add to Collection

Article Medicine, Research & Experimental

TLR3 deficiency impairs spinal cord synaptic transmission, central sensitization, and pruritus in mice

Tong Liu et al.

JOURNAL OF CLINICAL INVESTIGATION (2012)

Add to Collection

Article Dermatology

Long TSLP transcript expression and release of TSLP induced by TLR ligands and cytokines in human keratinocytes

Yang Xie et al.

JOURNAL OF DERMATOLOGICAL SCIENCE (2012)

Add to Collection

Article Cell Biology

Transcriptional activation of the IL31 gene by NFAT and STAT6

Keunhee Park et al.

JOURNAL OF LEUKOCYTE BIOLOGY (2012)

Add to Collection

Article Medicine, Research & Experimental

Endothelin-1 induces itch and pain in the mouse cheek model

Lenyta Oliveira Gomes et al.

LIFE SCIENCES (2012)

Add to Collection

Review Allergy

TSLP Expression: Cellular Sources, Triggers, and Regulatory Mechanisms

Toshiro Takai

ALLERGOLOGY INTERNATIONAL (2012)

Add to Collection

Letter Allergy

Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection

Alexander A. Navarini et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2011)

Add to Collection

Article Endocrinology & Metabolism

A study of serum concentrations and dermal levels of NGF in atopic dermatitis and healthy subjects

Alexandru D. P. Papoiu et al.

NEUROPEPTIDES (2011)

Add to Collection

Review Medicine, General & Internal

MECHANISMS OF DISEASE Filaggrin Mutations Associated with Skin and Allergic Diseases

Alan D. Irvine et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Add to Collection

Article Multidisciplinary Sciences

Analysis of cellular and behavioral responses to imiquimod reveals a unique itch pathway in transient receptor potential vanilloid 1 (TRPV1)-expressing neurons

Se-Jeong Kim et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)

Add to Collection

Review Biochemistry & Molecular Biology

The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses

Christian C. Yost et al.

BIOCHIMIE (2010)

Add to Collection

Article Allergy

Epidemiology of Atopic Dermatitis and Atopic March in Children

Jonathan M. Spergel

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA (2010)

Add to Collection

Article Immunology

Mouse and Human Eosinophils Degranulate in Response to Platelet-Activating Factor (PAF) and LysoPAF via a PAF-Receptor-Independent Mechanism: Evidence for a Novel Receptor

Kimberly D. Dyer et al.

JOURNAL OF IMMUNOLOGY (2010)

Add to Collection

Article Neurosciences

Toll-like receptor 7 mediates pruritus

Tong Liu et al.

NATURE NEUROSCIENCE (2010)

Add to Collection

Article Multidisciplinary Sciences

Targeting the Neurokinin Receptor 1 with Aprepitant: A Novel Antipruritic Strategy

Sonja Staender et al.

PLOS ONE (2010)

Add to Collection

Article Allergy

Increased serum thymic stromal lymphopoietin in children with atopic dermatitis

Eun Byoul Lee et al.

PEDIATRIC ALLERGY AND IMMUNOLOGY (2010)

Add to Collection

Article Dermatology

Nerve growth factor, neuropeptides and cutaneous nerves in atopic dermatitis

Latief et al.

INDIAN JOURNAL OF DERMATOLOGY (2010)

Add to Collection

Article Dermatology

Measuring the Prevalence of Chronic Itch in the General Population: Development and Validation of a Questionnaire for Use in Large-scale Studies

Uwe Matterne et al.

ACTA DERMATO-VENEREOLOGICA (2009)

Add to Collection

Article Biochemistry & Molecular Biology

Functional Analysis of the Thymic Stromal Lymphopoietin Variants in Human Bronchial Epithelial Cells

Michishige Harada et al.

AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2009)

Add to Collection

Review Immunology

Janus kinases in immune cell signaling

Kamran Ghoreschi et al.

IMMUNOLOGICAL REVIEWS (2009)

Add to Collection

Article Allergy

Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three

Joseph A. Odhiambo et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)

Add to Collection

Article Immunology

Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome

Anais Briot et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2009)

Add to Collection

Article Dermatology

Transgenic Expression of Interleukin-13 in the Skin Induces a Pruritic Dermatitis and Skin Remodeling

Tao Zheng et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)

Add to Collection

Article Neurosciences

Excitation of Mouse Superficial Dorsal Horn Neurons by Histamine and/or PAR-2 Agonist: Potential Role in Itch

Tasuku Akiyama et al.

JOURNAL OF NEUROPHYSIOLOGY (2009)

Add to Collection

Article Multidisciplinary Sciences

Cellular Basis of Itch Sensation

Yan-Gang Sun et al.

SCIENCE (2009)

Add to Collection

Article Medicine, General & Internal

Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis

Rosanne A. H. M. van den Oord et al.

BMJ-BRITISH MEDICAL JOURNAL (2009)

Add to Collection

Review Allergy

Rupatadine in allergic rhinitis and chronic urticaria

J. Mullo et al.

ALLERGY (2008)

Add to Collection

Article Immunology

Calcitonin Gene-Related Peptide Biases Langerhans Cells toward Th2-Type Immunity

Wanhong Ding et al.

JOURNAL OF IMMUNOLOGY (2008)

Add to Collection

Article Biotechnology & Applied Microbiology

A quantitative analysis of kinase inhibitor selectivity

Mazen W. Karaman et al.

NATURE BIOTECHNOLOGY (2008)

Add to Collection

Article Neurosciences

The itch-producing agents histamine and cowhage activate separate populations of primate spinothalamic tract neurons

Steve Davidson et al.

JOURNAL OF NEUROSCIENCE (2007)

Add to Collection

Article Allergy

Cytokine modulation of atopic dermatitis filaggrin skin expression

Michael D. Howell et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2007)

Add to Collection

Article Dermatology

Lifetime prevalence of self-reported atopic diseases in a population-based sample of elderly subjects:: results of the ESTHER study

M. Wolkewitz et al.

BRITISH JOURNAL OF DERMATOLOGY (2007)

Add to Collection

Article Allergy

Histamine H-4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus

Paul J. Dunford et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2007)

Add to Collection

Article Allergy

Clinical relevance of nerve growth factor serum levels in patients with atopic dermatitis and psoriasis

O. Schulte-Herbrueggen et al.

INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY (2007)

Add to Collection

Review Allergy

New perspectives on epidermal barrier dysfunction in atopic dermatitis: Gene-environment interactions

Michael J. Cork et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2006)

Add to Collection

Article Dermatology

Increased nerve growth factor and its receptors in atopic dermatitis:: an immunohistochemical study

Ying-Chun Dou et al.

ARCHIVES OF DERMATOLOGICAL RESEARCH (2006)

Add to Collection

Article Allergy

Neurotrophins in allergic diseases: From neuronal growth factors to intercellular signaling molecules

WA Nockher et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2006)

Add to Collection

Article Dermatology

Prevalence of atopic dermatitis in Japanese elementary schoolchildren

H Saeki et al.

BRITISH JOURNAL OF DERMATOLOGY (2005)

Add to Collection

Article Immunology

Human thymic stromal lymphopoietin promotes dendritic cell-mediated CD4+ T cell homeostatic expansion

N Watanabe et al.

NATURE IMMUNOLOGY (2004)

Add to Collection

Article Immunology

Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice

SR Dillon et al.

NATURE IMMUNOLOGY (2004)

Add to Collection

Article Dermatology

Prognosis and prognostic factors in adult patients with atopic dermatitis: a long-term follow-up questionnaire study

MH Sandstrom et al.

BRITISH JOURNAL OF DERMATOLOGY (2004)

Add to Collection

Article Neurosciences

Protease-activated receptor 2 sensitizes the capsaicin receptor transient receptor potential vanilloid receptor 1 to induce hyperalgesia

S Amadesi et al.

JOURNAL OF NEUROSCIENCE (2004)

Add to Collection

Article Biochemistry & Molecular Biology

GPL, a novel cytokine receptor related to GP130 and leukemia inhibitory factor receptor

C Diveu et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2003)

Add to Collection

Article Dermatology

Neuropeptides concentrations in the skin of a murine (NC/Nga mice) model of atopic dermatitis

M Katsuno et al.

JOURNAL OF DERMATOLOGICAL SCIENCE (2003)

Add to Collection

Article Dermatology

Serum levels of vasoactive intestinal peptide are elevated in patients with atopic dermatitis

N Umemoto et al.

JOURNAL OF DERMATOLOGICAL SCIENCE (2003)

Add to Collection

Article Dermatology

Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema

A Jarvikallio et al.

ARCHIVES OF DERMATOLOGICAL RESEARCH (2003)

Add to Collection

Article Dermatology

Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis

M Toyoda et al.

BRITISH JOURNAL OF DERMATOLOGY (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.